Caplin Point shares fell on Tuesday after the USFDA classified its Gummidipoondi facility as 'official action indicated'. The company said it does not expect any material impact on its financials or operations. It is working with the USFDA to address 10 observations and remains committed to maintaining high quality standards.

Caplin Point said it does not expect any material impact on its financials or operations due to the USFDA inspection or the 10 observations, as of yet.

Caplin Point Laboratories Ltd. on Tuesday, November 17, said the US drug regulator has classified Caplin Steriles' facility as 'official action indicated' (OAI).

The company, in an exchange filing, said the US Food and Drug Administration (USFDA) inspected Caplin Steriles' injectable and ophthalmic manufacturing facility in Gummidipoondi between August 13 and August 21, 2026. It said the USFDA concluded its inspection with 10 observations, determining the facility as 'official action indicated' (OAI).

"The USFDA has now determined that the inspection of the Caplin Steriles Ltd facility is 'official action indicated' (OAI)," the company said in an exchange filing.

OAI is the USFDA strictest classification. Plants with OAIs are generally required to be re-inspected by the US drug regulator officials to give it an all-clear.

Caplin Point said it does not expect any material impact on its financials or operations on account of the same, as of yet. The facility continues to manufacture and supply products and the company said it remains committed to maintaining the highest standards of quality, current good manufacturing practices and regulatory compliance.

It added that it is working with the USFDA to address the observations and demonstrate the effectiveness and sustainability of corrective and preventive actions.

Caplin Point said it will keep the exchanges informed if there is any further information regarding the same in the future.

Caplin Point reported its second quarter results last week. Its net profit increased 15.3% to ₹178 crore from ₹154.4 crore last year. Its revenue increased 18% to ₹630 crore from ₹534 crore in the second quarter last year.

The company's earnings before interest, taxes, depreciation and amortization (EBITDA) increased 18.1% to ₹223.4 crore from ₹189.2 crore in the previous fiscal. Its EBITDA margin expanded by 10 basis points to 35.5% from 35.4% in the year-ago period.

Shares of Caplin Point are extending their losses on Tuesday after the USFDA news, currently trading 2.1% lower at ₹2,298. The stock is still up 28% so far this year.